Bullous fixed drug eruption due to erlotinib: A rare case report
Fixed Drug Eruption is one of the most common cutaneous adverse drug reactions, of which the bullous variant is a more severe form. Epidermal growth factor (EGFR) inhibitors are one of the prime chemotherapeutic agents used recently in various malignancies. Most of the side effects of EGFR inhibitor...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-07-01
|
| Series: | Annals of Oncology Research and Therapy |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/aort.aort_36_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Fixed Drug Eruption is one of the most common cutaneous adverse drug reactions, of which the bullous variant is a more severe form. Epidermal growth factor (EGFR) inhibitors are one of the prime chemotherapeutic agents used recently in various malignancies. Most of the side effects of EGFR inhibitors are not severe and subside by decreasing the drug dosage. There is no case report of bullous fixed drug eruption caused by EGFR inhibitors; herein, we report a rare case of bullous fixed drug eruption triggered by erlotinib, an EGFR inhibitor. |
|---|---|
| ISSN: | 2772-8382 2772-8390 |